Clinical trials: Infliximab
Inflammatory Bowel Diseases
Study on the Correlation and Consistency of Measuring Biologic Drug Plasma Concentrations Based on Different Detection Methods
In recent years, biologics (such as infliximab, adalimumab, vedolizumab, and ustekinumab) have shown great potential in the treatment of inflammatory bowel disease (IBD), transforming the traditional treatment model for IBD.
- Trial name
- NCT06849739
- Testing
- biologic therapy(eg:IFX,ADA,UST,VDZ)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Graft-Versus-Host Disease
Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation
This study will evaluate the efficacy of infliximab in reducing the incidence of grade II-IV acute graft versus host disease by day +100 post-transplant in patients undergoing allogeneic hematopoietic stem cell transplant.
- Trial name
- NCT00201799
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Ankylosing Spondylitis
An Extension Study to Demonstrate the Equivalence of Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1
This open-label, single-arm, multicenter, multiple single-dose intravenous (IV) infusion, efficacy, and safety extension study of the Phase 1 Study CT-P13 1.1 is designed to assess the long-term efficacy and safety of multiple…
- Trial name
- NCT01571206
- Testing
- Infliximab
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Celltrion
Ulcerative Colitis
A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Ulcerative Colitis
The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Ulcerative Colitis.
- Trial name
- NCT00096655
- Testing
- Infliximab
- Volunteers
- 364 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Crohn's Disease
Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)
The current observational program was determined to collect data on the real life dosing regimen of Remicade in patients with Crohn's disease (CD) in the hospital and non-hospital setting.
- Trial name
- NCT00724958
- Testing
- Infliximab
- Volunteers
- 348 people
- Sponsor
- Merck Sharp & Dohme LLC
Inflammatory Bowel Disease, Crohn's Disease
Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease
Drug serum concentrations will be measured at several time-points for inflammatory disease patients treated with anti-TNF agents.
- Conditions
- Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
- Trial name
- NCT02073526
- Testing
- Infliximab, adalimumab, certolizumab pegol
- Where
- Norway
- Volunteers
- 1,230 people
- Sponsor
- Oslo University Hospital
Arthritis, Rheumatoid
A Placebo-Controlled, Double-Blinded, Randomized Trial of Remicade in Korean Patients With Rheumatoid Arthritis Despite Methotrexate (Study P04280)(COMPLETED)
Prior to the first infusion, patients will be randomized into one of two groups (placebo or infliximab). All patients will continue to receive the same does of methotrexate (MTX) during the study as received prior to the study.
- Trial name
- NCT00202852
- Testing
- MTX, Infliximab
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Spondyloarthritis
Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity
Patients with spondyloarthritis, already treated by TNF blocker (adalimumab, etanercept or infliximab), and in stable low disease activity for at least 6 months, will be randomized into 2 groups: either keeping on their usual…
- Trial name
- SPACING (NCT01610947)
- Testing
- Adalimumab, Etanercept, Golimumab or infliximab
- Where
- France
- Volunteers
- 398 people
- Sponsor
- University Hospital, Montpellier
Rheumatoid Arthritis
Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers
Comparing the structural effects of TNFi and tocilizumab on the periarticular bone by performing a comprehensive analysis of the periarticular bone changes in RA patients treated with either TNFi or tocilizumab in a longitudinal…
- Trial name
- Re-Bone (NCT02778789)
- Testing
- Tocilizumab, TNF-alpha Inhibitor
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Pediatric Ulcerative Colitis
Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis
The purpose of this study is to evaluate the the efficacy of TA-650 using Clinical activity index (CAI) score and other evaluation indicators in pediatric patients with moderate to severe ulcerative colitis after TA-650…
- Trial name
- NCT01585155
- Testing
- TA-650
- Where
- 7 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Tanabe Pharma Corporation
Crohn's Disease
Efficacy Study of Pneumococcal Vaccination in Crohn's Disease
A growing number of patients with Crohn's disease are treated with immunosuppressive agents, such as anti-tumor necrosis factor blockers and immunomodulators.
- Trial name
- NCT01505855
- Testing
- 23-valent polysaccharide pneumococcal vaccine
- Where
- 15 sites in South Korea
- Volunteers
- 197 people
- Sponsor
- Kyunghee University Medical Center
Rheumatoid Arthritis
Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World"
Rheumatoid arthritis (RA) is a chronic and disabling disease. tumor necrosis factor-a(TNF-a) inhibitors have demonstrated an outstanding performance in relieving joint inflammation and retarding bone erosion involved in RA.
- Trial name
- NCT02878161
- Testing
- methotrexate(necessary), infliximab, etanercept
- Volunteers
- 240 people
- Sponsor
- Fen Li
Depression
A Study of Infliximab for Treatment Resistant Major Depression
Major depression is increasingly recognized to be a chronic and highly recurrent condition, which results in significantly increased health problems.
- Trial name
- Infliximab (NCT00463580)
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Ankylosing Spondylitis
Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)
This study is the trial to demonstrate how our product is similar to remicade by comparing the results of blood samples in active Ankylosing Spondylitis patients.
- Trial name
- NCT01220518
- Testing
- Infliximab
- Where
- South Korea
- Volunteers
- 257 people
- Sponsor
- Celltrion
Spondylitis, Ankylosing
Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)
This is an open-label, controlled sub-study to the parent protocol (P04041, NCT00779935) to examine the expression profile of genes in patients in the active stage of ankylosing spondylitis (AS) compared to the healthy population…
- Trial name
- NCT00778869
- Testing
- Remicade
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Crohn's Disease
Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease
OBJECTIVES: I. Evaluate the efficacy of chimeric monoclonal antibody (cA2) compared with placebo in closure of enterocutaneous fistulae in patients with Crohn's disease.
- Trial name
- NCT00004941
- Testing
- monoclonal antibody cA2
- Volunteers
- 94 people
- Sponsor
- FDA Office of Orphan Products Development
Colitis, Ulcerative
TITRATE (inducTIon for acuTe ulceRATivE Colitis)
The aim of this study is to investigate whether intensive, personalized IFX dosing by using a pharmacokinetics driven dashboard system during the induction phase in patients with acute severe UC leads to increased treatment…
- Trial name
- TITRATE (NCT03937609)
- Testing
- Infliximab
- Where
- 7 sites in Ireland, Netherlands and 1 more
- Volunteers
- 50 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Crohn Disease
Impact of Infliximab in Fistulizing Crohn's Disease on Health Care Resources (Study P04204)(TERMINATED)
A multi-centre retrospective review of fistulizing Crohn's disease (CD) patient charts will capture data to measure health care resource utilization associated with the use of Infliximab for treatment of CD.
- Trial name
- NCT00705471
- Testing
- Infliximab
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatic Disease
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating…
- Trial name
- NCT07138898
- Testing
- Methotrexate, Sulfasalazine, Hydroxychloroquine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- NYU Langone Health
Rheumatoid Arthritis
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Approximately 30% of patients with rheumatoid arthritis have an inadequate response to anti-TNF (primarily or loss of response), leaving two alternatives: rotation to a second anti-TNF or change of biologic, with a different…
- Trial name
- ROC (NCT01000441)
- Testing
- infliximab, etanercept, adalimumab, abatacept, rituximab or tocilizumab
- Where
- 44 sites in France, Monaco
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France